Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2003

View Archived Issues

Two series of GSK-3 kinase inhibitors discovered by Lilly researchers

Takeda claims JNK inhibitors for heart failure, arthritis and other uses

Ferring presents new plasma kallikrein inhibitors for use in inflammatory disorders

Novel 5-HT receptor ligands reported in recent patent

Optically active IKK-beta inhibitor covered by Bayer patent

Novel antimalarial artemisin derivatives reported in Bayer patent

Tigecycline as an alternative to vancomycin in MRSA osteomyelitis

Chemokine inhibition as potential novel therapy for endometriosis, postsurgical adhesions

ACP-2127 advanced into preclinical testing

Archemix selects ARC-183 for development

AstraZeneca and Abgenix enter cancer antibody alliance

FDA accepts for filing NDA for ultra-low-dose transdermal estrogen patch

Cardiome and Fujisawa enter RSD-1235 partnership

IDM to coordinate Europe project for optimization of prostate cancer vaccine

Medicure seeks clearance to begin phase II study of MC-1 in CABG patients

Oxytrex phase II study meets endpoints

Visudyne approved in Japan for wet AMD

Titan acquires congestive heart failure drug DITPA

SBIR grant funds development of niprisan for sickle cell disease

Community-based trial compares Concerta and Strattera for ADHD

Liraglutide has beneficial effects on food intake and body weight in obese minipigs

Vasopressin V2 receptor antagonist effective in early and established polycystic kidney disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...